Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29589279 | 0.97 | POLB (0.69) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| Acetic Acid SCHEMBL28756645 | 0.97 | POLB (0.69) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| Sulfuric Acid SCHEMBL28756502 | 0.91 | POLB (0.63) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL11551428 | 0.88 | POLB (0.75) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL11325469 | 0.88 | LMNA (0.83) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL4028956 | 0.85 | POLB (0.71) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7123707 | 0.85 | NPSR1 (0.55) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL30539486 | 0.85 | NPSR1 (0.55) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL2766319 | 0.84 | POLB (0.62) | POLBLMNAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL733777 | 0.84 | KMT2A (0.69) | ALDH1A1CYP2C9CYP2C19GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103420895-A | Preparation method of 4-aminoindole | ASCEPION PHARMACEUTICALS INC | 2013-12-04 | — | — | CN | claimed |
| CN-103420895-A | Preparation method of 4-aminoindole | ASCEPION PHARMACEUTICALS INC | 2013-12-04 | — | — | CN | disclosed |
| US-6747051-B2 | BLADDER UROGENITAL DISORDERS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-08 | — | — | US | disclosed |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6602897-B2 | For example, 2-((2-bromo-3-chloro-5-dimethylamino-6-methylphenyl)imino)imid azolidine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1328517-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002032876-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
| US-5254135-A | Applying indole dye, developing with oxidizing system | L'OREAL (FR) | 1993-10-19 | — | — | US | disclosed |
| US-4552981-A | Process for the production of 5-nitro-acet-2,4-xylidine | MOBAY CHEMICAL CORPORATION (US) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | RXFP1, RXFP3, PRMT1 | POLB 2982/4885LMNA 4121/4885ALDH1A1 863/4885 |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | HRH2, RXFP3, AREG | POLB 1940/4885LMNA 4168/4885ALDH1A1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.